Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Takeda Pharmaceutical: New Drug Application Approval in Japan for Copaxone® Subcutaneous Injection 20 mg Syringe, a Drug for the Treatment of Multiple Sclerosis
Altered likelihood of brain activation in attention and working memory networks in patients with multiple sclerosis: An ALE meta-analysis.
Fatal Acute Myeloid Leukemia With 11q23 MLL Gene Rearrangement Following Mitoxantrone Treatment in a Case of Childhood-onset Multiple Sclerosis.
Genzyme’s Lemtrada Approved by the FDA
Low Dose Naltrexone: Side Effects and Efficacy in Gastrointestinal Disorders.
Cyclophosphamide
The majority of CD1d-sulfatide-specific T cells in human blood use a semiinvariant Vδ1 TCR.
Heterogeneity of serum gelatinases MMP-2 and MMP-9 isoforms and charge variants.
First-in-class thyrotropin-releasing hormone (TRH)-based compound binds to a pharmacologically distinct TRH receptor subtype in human brain and is effective in neurodegenerative models.
Receptos Initiates SUNBEAM Phase 3 Trial of RPC1063 in Relapsing Multiple Sclerosis
A novel pH-sensitive interferon-β (INF-β) oral delivery system for application in multiple sclerosis.
Accentia Biopharmaceuticals Conducts Investigator Meeting in Preparation for New Multiple Sclerosis Drug Study for Cyrevia™
BTG plc Close Period Update
More to come: humoral immune responses in MS.
IgE-Mediated Allergic Reactions after the First Administration of Glatiramer Acetate in Patients with Multiple Sclerosis.
Childhood obesity and risk of pediatric multiple sclerosis and clinically isolated syndrome.
Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis (MIRROR)
A urinary test procedure for identification of cannabidiol in patients undergoing medical therapy with marijuana.
The correlation between symptomatic fatigue to definite measures of gait in people with multiple sclerosis.
Daclizumab Therapy for Multiple Sclerosis.
Receptos announces issuance of composition of matter patents covering proprietary lead product candidate RPC1063
Immunological and short-term brain volume changes in relapsing forms of multiple sclerosis treated with interferon beta-1a subcutaneously three times weekly: an open-label two-arm trial.
The Effect of Glatiramer Acetate Therapy on Functional Properties of B Cells From Patients With Relapsing-Remitting Multiple Sclerosis.
The Clinical Meaning of Walking Speed as Measured by the Timed 25-Foot Walk in Patients With Multiple Sclerosis.
Involvement of AMPK, IKβα-NFκB and eNOS in the sildenafil anti-inflammatory mechanism in a demyelination model.

Pages